Q-omics provides the consensus-scored STAC profile across patient tissues and cancer cell-line models. STAC expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STAC is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, STAC RNA expression shows 16,342 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, THCA, and BRCA as cancer lineages where STAC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAC survival associations across molecular data types. STAC RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAC RNA expression–survival associations across cancer types. High STAC expression shows unfavorable associations in UCEC, KIRP, LGG and MESO, but favorable associations in ACC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STAC RNA expression.
This table summarizes STAC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for STAC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAC shows lower tumor expression in KIRC, LUSC, BLCA, LUAD and UCEC and higher tumor expression in THCA. The THCA box plot shows higher STAC RNA expression in tumor versus normal tissue (log2 FC = +2.812, t-test p < 0.001).
This table shows molecular features associated with STAC in patient tissues and cancer cell lines. In patient samples, STAC shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, STAC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BREAST.
